Golden
Auransa

Auransa

A biotechnology company applying AI and genomics to precision medicine to address patient subpopulations that have unmet needs. Their pipeline of drug candidates address cancer, neurology, inflammation, infectious disease and metabolic disease. It is located in Palo Alto, California and was founded in 2014.

Auransa is a California-based artificial technology company specializing in precise pharmaceuticals. At the core of its platform, the company predicts treatments, initiates drug discovery and research, identify patients who could use the pharmaceutical in trials, and monitors said patients. 

Product

The company has developed multiple products, such as the SMarTR Engine, and CTSeek Liquid Biopsy Technology. The SMarTR Engine uses machine learning, advanced analytics and mathematics in an AI framework to predict disease subtypes. Auransa has discovered patient subtyes for 30 disease and is utilizing the SMarTR Engine to find more. 



The CTSeek is used for clinical trials and is a liquid biopsy diagnostic technology which generates insights from molecular data to understand the biology of disease and patient subtypes. The information is combined with in-house drug discovery and development for identification of novel compounds to address unmet medical needs for disease subtypes that are clinically meaningful. 





Timeline

People

Name
Role
Related Golden topics

Pek Lum

Founder



Viwat Visuthikraisee

Founder



Further reading

Title
Author
Link
Type
Date

Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee's Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia

Auransa

Web

December 19, 2018

Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References